Compare Becton Dickinson and Co (BDX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Vale SA — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Vale SA trades at $14.35 (market cap $62.26B). The key difference: Vale SA is the larger of the two by market cap, and Vale SA pays the higher dividend (8.12%). Which is the better fit depends on your goals.
| BDX | VALE | |
|---|---|---|
Market Cap | $48.93B | $62.26B |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $17.82 |
52-Week Low | $138.62 | $9.71 |
Enterprise Value | $65.03B | $78.50B |
Dividend Yield | 2.34% | 8.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
VALE trades at $14.71, showing minimal daily movement with a slight decline of 0.07%. The stock faces technical bearish signals from moving averages while fundamentals reveal mixed performance with declining net income margins from 42.85% in 2022 to 5.11% in 2026, despite recent revenue stabilization. Recent earnings misses in Q4 2025 and Q1-Q2 2026 highlight operational challenges, though the company maintains strong cash flow generation of $8.8 billion from operations in 2025.
VALE presents a cautious investment case with analyst consensus leaning neutral (51.35% hold) despite a $16.79 price target suggesting 14% upside. Key opportunities include copper segment growth and disciplined capital returns, while risks involve rising operational costs, earnings volatility, and governance concerns highlighted by recent board disputes. The stock's valuation at 29.42 P/E appears stretched given profitability declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
